Deutsche Bank Ag\ Gemini Therapeutics, Inc. Transaction History

Deutsche Bank Ag\

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$1.22 - $1.73 $14,509 - $20,574	-11,893 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$1.29 - $3.08 $54,993 - $131,303	-42,631 Reduced 78.19%	11,893 $17,000
Q4 2021 Feb 11, 2022	BUY	$2.39 - $4.0 $1,706 - $2,856	714 Added 1.33%	54,524 $159,000
Q3 2021 Nov 04, 2021	SELL	$3.3 - $6.32 $1,339 - $2,565	-406 Reduced 0.75%	53,810 $217,000
Q2 2021 Aug 11, 2021	BUY	$6.32 - $14.02 $82,191 - $182,330	13,005 Added 31.56%	54,216 $351,000
Q1 2021 May 13, 2021	BUY	$11.32 - $18.0 $466,508 - $741,798	41,211 New	41,211 $558,000

2.44M

Ticker GMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,244,500
Market Cap $1.05B
Description
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 ...

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

Stay updated on Deutsche Bank Ag\ with notifications on news.